Original researchMifepristone 100 mg in abortion regimens☆
Section snippets
Materials and methods
This clinical trial was approved by the Institutional Review Board of Magee-Womens Hospital of the University of Pittsburgh Health System. Entry criteria included 1) age at least 18 years, 2) a singleton intrauterine pregnancy not exceeding 49 days’ gestation as documented by vaginal ultrasound, 3) request for an abortion, 4) willingness to comply with the visit schedule, 5) willingness to have a surgical abortion if indicated, 6) adequate venous access for multiple phlebotomies, and 7) access
Results
Patient characteristics are presented in Table 1. All 80 subjects used the misoprostol, although histories obtained at first follow-up suggested that two women in group 1 and one woman in group 2 might have aborted before using the misoprostol. All but one of the women in group 1 (98%) and 38 (95%) of the women in group 2 used the misoprostol 48 hours ± 30 minutes after administration of mifepristone. The three women who did not use misoprostol during this time inserted the misoprostol tablets
Discussion
Mifepristone at doses less than the 600 mg, standardly used throughout most of the world, is known to be clinically effective. Two randomized studies demonstrated equal efficacy of regimens using either 200 or 600 mg of mifepristone followed in 48 hours by a misoprostol dose of 400 μg orally6 or 600 μg orally.7 In addition, a retrospective analysis by Ashok et al8 of data from 2000 women using mifepristone 200 mg followed in 48 hours by misoprostol 800 μg vaginally demonstrated complete
References (28)
- et al.
Abortion with mifepristone and misoprostolRegimens, efficacy, acceptability and future directions
Am J Obstet Gynecol
(2000) - et al.
Use of various ultrasound criteria to evaluate the efficacy of mifepristone and misoprostol for medical abortion
Am J Obstet Gynecol
(1999) - et al.
Low-dose mifepristone 200 mg and vaginal misoprostol for abortion
Contraception
(1999) - et al.
Low-dose mifepristone followed by vaginal misoprostol at 48 hours for abortion up to 63 days
Contraception
(2000) - et al.
Pharmacokinetics and metabolism of RU 486
J Steroid Biochem
(1987) Pharmacokinetics of the antiprogesterone RU 486 in women during multiple dose administration
J Steroid Biochem
(1989)- et al.
Pharmacokinetic study of RU 486 and its metabolites after oral administration of single doses to pregnant and non-pregnant women
Contraception
(1993) - et al.
Quantitation of RU 486 in human plasma by HPLC and RIA after column chromatography
Contraception
(1986) - et al.
Safety, efficacy, and acceptability of medical abortion in China, Cuba, and IndiaA comparative trial of mifepristone-misoprostol versus surgical abortion
Am J Obstet Gynecol
(1997) - et al.
Mifepristone-misoprostol medical abortionHome administration of misoprostol in Guadeloupe
Contraception
(1999)
Conceptual age and ultrasound measurements of gestational sac and crown-rump length in in vitro fertilization pregnancies
Fertil Steril
Early abortion with 800 μg of misoprostol by the vaginal route
Contraception
The use of misoprostol for termination of early pregnancy
Contraception
Early pregnancy termination with intravaginally administered sodium chloride solution-moistened misoprostol tabletsHistorical comparison with mifepristone and oral misoprostol
Am J Obstet Gynecol
Cited by (0)
- ☆
Supported by the Departmental Research Fund, Magee-Women’s Research Institute Family Planning Research Fund.